Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell ...

Shares of the iPhone maker rose nearly 3%, building on the previous session's rally. Apple announced an extra $100 billion ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

A legacy ranch in Jackson Hole, WY, has come onto the market, with records showing it is owned by former Eli Lilly exec Dr.